7 results
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
16 Apr 24
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
9:31pm
trial is incredibly exciting. I am deeply committed to our mission and look forward to contributing to our success in bringing new treatments to patients … is licensed to practice medicine in Massachusetts.
“I strongly believe in the company's mission and commitment to ALS and I have great faith
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
20 Dec 23
BrainStorm Issues 2023 Letter to Shareholders
5:04pm
interests.
We thank you for your continued support. Your faith in our mission fuels our determination to overcome the recent challenges
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
30 Mar 23
BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update
7:18am
on our mission of improving the lives of individuals with ALS.”
Fourth Quarter 2022 and Recent Highlights
U.S. Food and Drug Administration (FDA
8-K
EX-99.1
BCLI
Brainstorm Cell Therapeutics, Inc.
29 Oct 21
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
4:05pm
and world view, and we look forward to his guidance as we approach a new phase of our mission."
Menghis Bairu, MD, commented, "I have spent my entire … to serve on Brainstorm's board and participate in the company's mission and strategy. As a backer of transformative life-sciences, healthcare
8-K
EX-99.1
vqaq1
21 Jul 17
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
12:00am
- Prev
- 1
- Next